Antibody-drug conjugates represent a pivotal advancement in oncology, offering highly targeted cancer treatments that combine precision and potency. However, developing these therapies comes with significant challenges, from their intricate design to safety and resistance issues. This webinar will provide a comprehensive overview of these obstacles and deliver actionable insights into overcoming them.
Attendees will gain a deep understanding of preclinical strategies that address antibody-drug conjugate development hurdles, including in vitro and in vivo evaluation methods essential for optimizing antibody-drug conjugate performance. Additionally, the session will cover the regulatory landscape, emphasizing the importance of early engagement with regulatory bodies and strategic planning to ensure smooth Investigational New Drug (IND) submissions and regulatory approval.
The webinar also features case studies of successful antibody-drug conjugate therapies, highlighting the key factors that contributed to their approval and clinical success. These real-world examples will showcase innovative approaches that are shaping the future of antibody-drug conjugate development. The attendees will learn how to streamline the path from preclinical evaluation to clinical success, ensuring their antibody-drug conjugate therapies are positioned for success in a highly competitive market.
Download this webinar to learn:
- The complexities of antibody-drug conjugate design, safety concerns and mechanisms of resistance in oncology drug development
- In vitro and in vivo models that optimize antibody-drug conjugate performance, including essential assays for antibody-drug conjugate efficacy and safety
- How early engagement with regulatory agencies and strategic study design can streamline the IND submission process
- Real-world case studies of successful antibody-drug conjugate therapies and emerging trends that are shaping the future of antibody-drug conjugate development
